13 August 2026
13 August 2026
The latest round brings the total capital raised by Remepy to $62m.
The trial has enrolled 477 patients at 32 investigational sites located in the US and Europe.
The study will assess the tolerability and safety of two dose levels of DSP-3077 delivered via a single subretinal injection.
The device will be sold initially in the US and Canada, with further submissions planned in additional markets.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
